What is VolitionRx?
VolitionRx is a multinational epigenetic company dedicated to improving health outcomes through the earlier detection, diagnosis, and monitoring of life-altering diseases. The company is developing and commercializing simple, cost-effective blood tests designed to identify various conditions, including certain cancers and diseases associated with NETosis, such as sepsis. Their focus on epigenetics aims to revolutionize how diseases are managed by providing accessible diagnostic tools.
How much funding has VolitionRx raised?
VolitionRx has raised a total of $11.3M across 4 funding rounds:
Private Equity
$1.5M
Debt
$5.5M
Stock/Share Issuance
$2M
Other Financing Round
$2.3M
Private Equity (2022): $1.5M with participation from Namur Invest Capital Risk
Debt (2023): $5.5M, investors not publicly disclosed
Stock/Share Issuance (2026): $2M supported by The Lind Partners
Other Financing Round (2026): $2.3M featuring Wallonie Entreprendre and Namur Invest
Key Investors in VolitionRx
Wallonie Entreprendre
Wallonie Entreprendre is a company operating in the restaurant industry, indicating a potential interest in diversified investments or companies with strong regional economic impact.
Namur Invest
Namur Invest is a financial partner for businesses in the Namur province, offering financing solutions for projects with development potential and a focus on creation, innovation, and growth. Their involvement suggests a strategic interest in supporting regional economic development through innovative companies.
The Lind Partners
The Lind Partners is an institutional fund manager specializing in providing growth capital to small- and mid-cap companies. Their investment in VolitionRx indicates a belief in the company's potential for significant expansion and market leadership.
What's next for VolitionRx?
The recent major strategic investment positions VolitionRx for accelerated growth and expanded commercialization efforts. This capital infusion is expected to fuel further research and development, enhance market penetration for their diagnostic tests, and potentially explore new therapeutic monitoring applications. The company's trajectory suggests a strong emphasis on scaling operations and solidifying its market presence in the diagnostic and epigenetic sectors.
See full VolitionRx company page
